The Establishment of a Public Docket and Request for Comments for the Vaccines and Related Biological Products Advisory Committee Meeting
Below is an excerpt from a public comment submitted to the Food and Drug Administration in regard to the Establishment of a Public Docket and Request for Comments for the Vaccines and Related Biological Products Advisory Committee Meeting, on March 4, 2026.
Dear Commissioner of Food and Drugs:
I appreciate the Food and Drug Administration’s (FDA’s) establishment of a public docket for the Vaccines and Related Biological Products Advisory Committee (VRBPAC) proceedings and its invitation for stakeholder comment. This process strengthens regulatory deliberations that directly affect vaccine policy and public confidence in vaccines.
I submit these comments in my capacity as a public health researcher with expertise in vaccine communication strategies, primary care delivery, and determinants of vaccine uptake. My doctoral dissertation at Columbia University and subsequent postdoctoral work funded by the National Institute on Minority Health and Health Disparities (NIMHD) examined how federal authority, trust, and evidence communication shape public acceptance of vaccination programs.